Core Insights - The eighth China International Import Expo (CIIE) is held in Shanghai from November 5 to 10, focusing on "New Era, Shared Future" and featuring six major exhibition areas, showcasing 461 new products, technologies, and services, including future industries like low-altitude economy and humanoid robots [1] - CIIE serves as a platform for promoting international economic cooperation and mutual benefits, injecting positive energy into both the Chinese and global economies [1] - Amway, celebrating its 30th anniversary in China, showcases its health products and solutions at CIIE, emphasizing its commitment to enhancing public health and contributing to China's health initiatives [1][4] Amway's Strategic Focus - Amway's chairman highlights the expo's role in providing global companies with insights into the Chinese market, reinforcing Amway's confidence in continued investment in China [4] - The company plans to enhance its investment in China, focusing on extending, expanding, and supplementing its supply chain to contribute to the modernization of China's industrial system [4][12] Health Consumption Trends - The Chinese government's promotion of health consumption is reflected in the popularity of the medical devices and healthcare exhibition area at CIIE, with Amway launching a new vitamin and mineral supplement product, nicknamed "Little Gold Powder," aimed at addressing nutritional imbalances [5] - Amway showcases a range of anti-aging products and health solutions, including those targeting cellular aging, bone density, cognitive health, and skin health, utilizing plant-based nutrients as core ingredients [6] Innovation and R&D - Amway has established a comprehensive local R&D system for traditional Chinese medicine in China, collaborating with various partners to modernize and standardize herbal cultivation [8] - The company has initiated a five-year investment plan of 2.1 billion RMB, focusing on upgrading production facilities, enhancing digital infrastructure, and expanding its experience centers across China [15] Market Position and Future Outlook - Amway has been operating in China for 30 years and has consistently aligned its growth with China's economic development, making it the largest market for Amway globally for 22 consecutive years [9] - The company views China as a strategic growth engine and plans to leverage the country's diverse market opportunities for future investments [12]

Core Insights - The 8th China International Import Expo (CIIE) is being held in Shanghai from November 5 to 10, showcasing 461 new products, technologies, and services across six major exhibition areas, emphasizing the importance of international trade cooperation and mutual benefits [1][2] - Amway China is leveraging the CIIE to highlight its commitment to health products and services, showcasing innovative solutions to meet the diverse health needs of the public [2][3] Group 1: CIIE Overview - The CIIE serves as a platform for global enterprises to tap into the Chinese market, promoting international economic cooperation and injecting positive energy into both the Chinese and global economies [1] - The event features new themes such as the silver economy, ice and snow economy, and sports economy, along with new consumption platforms focusing on digital and health consumption [1] Group 2: Amway's Commitment and Innovations - Amway China is focusing on health consumption, launching a new multi-vitamin and mineral powder product, "Little Gold Powder," which is the first "blue hat" multi-nutrient product in the Chinese market [3] - The company is showcasing a range of anti-aging products aimed at improving health expectancy, including solutions for cellular health, mobility, brain function, and skin health [3] Group 3: Research and Development - Amway has established a plant research center in Wuxi, integrating traditional Chinese medicine with modern biomedical approaches through its "Shennong" system, which includes extensive data on herbal remedies and health solutions [4] - The company is building a comprehensive local research and development system for traditional Chinese medicine, collaborating with various institutions to innovate and modernize agricultural practices [4] Group 4: Investment Plans - Amway has initiated a five-year investment plan of 2.1 billion RMB (approximately 0.3 billion USD) from 2023 to 2027, focusing on upgrading production facilities, enhancing digital infrastructure, and expanding experience centers [6] - The investment plan aims to strengthen Amway's supply chain and innovation capabilities in China, reinforcing its position as a strategic growth engine [6] Group 5: Strategic Alignment - Amway's strategies align with China's national goals of health and well-being, emphasizing digital infrastructure upgrades and a robust supply chain to support the health and wellness sector [7] - The company has successfully transitioned to a "second entrepreneurship" in China, with innovations and business models developed in China being adopted in other markets [7]

Core Insights - The article highlights the significant growth and transformation of multinational pharmaceutical companies in China over the past eight years, particularly through their participation in the China International Import Expo (CIIE) [11] - Companies like Roche and Gilead are expanding their product offerings and localizing their operations, indicating a shift towards more comprehensive engagement in the Chinese market [3][5] Group 1: Roche's Expansion - Roche has evolved from showcasing a few oncology drugs at the first CIIE to presenting over 40 products and solutions this year, covering the entire industry chain from early research to localized production [3] - The company has launched nearly 15 products in China over the past eight years, with a new biopharmaceutical base in Shanghai aimed at producing large molecule antibody drugs locally [3][5] Group 2: Gilead's Innovations - Gilead is actively advancing local research and development, currently conducting 16 projects in China, including 10 in oncology, with 90% of these projects synchronized with global timelines [5] - The company introduced Lenacapavir, the first long-acting HIV prevention drug requiring only two doses per year, marking a significant milestone in HIV prevention [2][5] Group 3: AstraZeneca's Investments - AstraZeneca signed a $136 million investment agreement for its Qingdao base during the expo, emphasizing China's role as its second-largest market and a source of innovation [3] - The company has invested over $1.7 billion in projects driven by previous CIIE events, embedding its production supply chain deeply into the Chinese market [3] Group 4: Merck and Eli Lilly's Contributions - Merck showcased its first HIF-2α inhibitor for VHL syndrome patients and announced plans to introduce over 40 new products and indications in the next five years [5] - Eli Lilly has invested over 20 billion RMB in China, establishing a comprehensive industry chain from research to commercialization, and plans to continue expanding its local collaborations [5][10] Group 5: Amway's Local Innovations - Amway introduced a vitamin and mineral powder product, the first "blue hat" multivitamin in China, reflecting its commitment to local research and development [6][10] - The company has established a plant research center in Wuxi and is integrating AI and traditional Chinese medicine to enhance its product offerings [8][10] Group 6: The Broader Impact of CIIE - The CIIE has become a platform for global companies to redefine their roles in China, with many establishing local R&D centers and committing to long-term investments [10][11] - The event is seen as a bridge for innovation and trust between China and the world, showcasing the potential for Chinese-developed products to reach global markets [11][12]

Core Insights - The China International Import Expo (CIIE) is increasingly recognized as a platform for promoting international trade cooperation and mutual benefits, contributing positively to both the Chinese and global economies [1] Company Highlights - Amway, celebrating 30 years in China, showcased its health products and services at the CIIE, addressing the diverse health needs of the public through innovative solutions and research achievements [2] - Amway's Chairman and President, Yu Fang, emphasized the expo's role in enhancing global companies' confidence in investing in China, positioning the country as a strategic market for Amway [4] - Amway launched a new product, a multi-vitamin and mineral powder called "Little Gold Powder," aimed at addressing nutritional imbalances in the Chinese diet, marking it as the first "blue hat" multi-nutrient powder in the market [5] Product Innovations - Amway presented a range of anti-aging products focused on improving healthspan, utilizing plant-based nutrients to enhance quality of life [7] - The company also highlighted products targeting metabolic health, dietary balance, and weight management, showcasing a comprehensive approach to health solutions [8] - Amway's Nutrilite brand is centered on plant nutrients, with significant investments in research and development, including a plant research center in Wuxi and the integration of AI technology for product development [8][10] Investment and Growth Strategy - Amway has initiated a five-year investment plan of 2.1 billion yuan (approximately 300 million USD) from 2023 to 2027, focusing on upgrading production facilities, digital infrastructure, and enhancing research capabilities [13] - The company aims to strengthen its supply chain and innovation capabilities in China, reinforcing its position as a strategic growth engine [14] - Amway's long-term commitment to the Chinese market is evident, with a focus on aligning its development with national strategies for health and well-being [12][14]